Clinical Trial Update: The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the biological activity of cediranib (AZD2171) in gastrointestinal stromal tumors and related soft tissue sarcomas; results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Soft Tissue Sarcoma

Drugs mentioned

• Cediranib (Cediranib)

Snippet

Sponsor: AstraZeneca | Conditions: Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas | Phase 2 | Status: COMPLETED | Results posted: 2012-07-16